CD33 and acute myeloid leukemia: The anti-CD33-antibody we use is gemtuzumab, which is known as the internalizing part of gemtuzumab-ozogamicin (Mylotarg®, GO), an antibody–drug conjugate approved for AML in a combination therapy with chemotherapy [20].